A class of lipopeptide antifungal drugs that act by inhibiting glucan synthesis, thereby damaging fungal cell walls. They are effective against Candida and Aspergillus species. Examples are caspofungin (Cancidas) and micafungin.
Echinocandins are available in an intravenous dosage form and have medium to high efficacy in the treatment of serious Candida infections such as invasive candidiasis, esophageal candidiasis and systemic candidiasis.
GBI Research, the leading business intelligence provider has released its latest research "Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth", which provides an insight into antifungals sales and price forecasts until 2017.
Echinocandins are effective in patients with invasive candidiasis and recommended as first-line therapy, especially for patients with severe sepsis or those previously exposed to azoles or infected with Candida glabrata (1).